Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
VTRSPITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to...
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
VTRSPITTSBURGH, Dec. 17, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026. The Company's presentation and fireside chat...
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
VTRSViatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Compete Restrictions PITTSBURGH, Dec. 6, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has entered into...
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
VTRSApproval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity PITTSBURGH, Aug. 11, 2025 /PRNewswire/...
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance
VTRSDelivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global Business Positive Results From Five Phase 3 Data Readouts This Year Reinforce Continued Momentum of Late-Stage Pipeline Returns More Than $630 Million of...
Goldman Sachs Initiates Coverage On Viatris with Neutral Rating, Announces Price Target of $10
VTRSPeering Into Viatris's Recent Short Interest
VTRSViatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars
VTRSViatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS guidance.
Viatris Raises FY2025 Adj EPS Guidance from $2.12-$2.26 to $2.16-$2.30 vs $2.21 Est; Affirms FY2025 Sales Guidance of $13.50B-$14.00B vs $13.82B Est
VTRSViatris Q1 Adj. EPS $0.50 Beats $0.49 Estimate, Sales $3.25B Beat $3.24B Estimate
VTRSViatris Reports Phase 3 Results for Low-Dose Birth Control Patch With Strong Safety Profile
VTRSViatris Reports Phase 3 Results for Fast-Acting Pain Drug, Shows Less Opioid Use
VTRSViatris Has Filed Applications To The Ministry Of Health, Labor And Welfare For Approval Of Effexor SR Capsules (Venlafaxine Hydrochloride) For Generalized Anxiety Disorder
VTRSViatris Agrees To $335 Million Opioid Settlement Framework
VTRSViatris reached a $335 million settlement framework to resolve opioid lawsuits, addressing over 1,000 U.S. and Canadian legal claims tied to its products.
Viatris Reached A Nationwide Settlement Framework To Resolve Opioid-related Claims By States, Local Governments, And Tribes Against The Company And Certain Of Its Subsidiaries, The Company Would Pay Up To A Maximum Of $335M
VTRSJefferies Maintains Buy on Viatris, Lowers Price Target to $13
VTRSForecasting The Future: 4 Analyst Projections For Viatris
VTRSPiper Sandler Reiterates Neutral on Viatris, Lowers Price Target to $10
VTRSBarclays Maintains Underweight on Viatris, Lowers Price Target to $9
VTRSB of A Securities Maintains Underperform on Viatris, Lowers Price Target to $10
VTRSViatris Stock Tumbles On Q4 Earnings Miss, FDA Warning Clouds 2025 Outlook
VTRSViatris missed Q4 estimates with an 8% revenue decline. 2025 guidance falls short as FDA import alert hits sales. Share repurchases prioritized.
Viatris FY2025 Outlook: Adj EPS $2.12-$2.26 vs $2.60 Estimate; Sees Sales $13.500B-$14.000B vs $14.31B Estimate
VTRSViatris Q4 2024 Adj EPS $0.54 Misses $0.57 Estimate, Sales $3.52B Miss $3.61B Estimate
VTRSViatris Exec Says Co Is Uniquely Positioned To Be Able To Be A Long Term Player In The Market For Obesity Treatments
VTRSViatris Issues Statement Regarding Receipt Of Warning Letter And Import Alert For Indore, India Facility; The Import Alert Affects 11 Actively Distributed Products That Will No Longer Be Accepted Into The U.S. Until The Warning Letter Is Lifted
VTRSViatris Q1 2022 Earnings Conference Call On May 9, 2022 At 08:30 AM ET
VTRSViatris (NASDAQ:VTRS) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.
